

Entrez PubMed

EXHIBIT 1

JAN 09 2007

Page 1 of 1

A service of the National Library of Medicine
and the National Institutes of HealthMy NCBI
[\[Sign In\]](#) [\[Register\]](#)

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search PubMed for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display AbstractPlus Show 20 Sort by Send to

All: 1 Review: 0

1: [Clin Appl Thromb Hemost](#). 2001 Jul;7(3):209-13.

Links

Individual dosing of ASA prophylaxis by controlling platelet aggregation.**Syrbe G, Redlich H, Weidlich B, Ludwig J, Kopitzsch S, Gockelfitz A, Herzog T.**Department of Internal Medicine, District Hospital of
Stadtroda/Thuringia, Germany. helgeredlich@t-online.de

Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.

PMID: 11441981 [PubMed - indexed for MEDLINE]

Display AbstractPlus Show 20 Sort by Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)**Related Links**

In vitro bleeding test with PFA-100- aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. [J Thromb Thrombolysis. 2001]

[Acetylsalicylic acid (ASA) resistance in patients with Ischemic heart disease (IHD) as bioindicator of the treatment strategy] [Cas Lek Cesk. 2005]

Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. [Eur J Clin Pharmacol. 1998]

Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. [Cerebrovasc Dis. 2005]

Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. [Thromb Res. 2004]

See all Related Articles...

Dec 18 2006 06:34:27

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPl> 1/2/2007

BEST AVAILABLE COPY